StocksMedium•5 October 2026•
1 min read
Rezolute Shares Rise as FDA Recommends Meeting for Rare Blood Sugar Drug
Key Facts
1The FDA recommended a pre-BLA meeting for Rezolute's congenital hyperinsulinism drug, ersodetug, despite the study missing primary endpoints.
The U.S. Food and Drug Administration (FDA) recommended a pre-Biologics License Application (pre-BLA) meeting for Rezolute's drug, ersodetug. Benzinga reported that the recommendation for the congenital hyperinsulinism treatment comes despite the clinical study missing its primary endpoints.
RZLT closed at $4.01 on October 2, 2026, with the stock reaching a day high of $4.2 and a low of $3.97 during that session. The FDA's willingness to move forward with a meeting suggests a potential regulatory path for the rare disease treatment, driving investor optimism regarding the company's clinical pipeline.